Thus, PD‐1/PD‐L1 immune checkpoint inhibitors are aimed at nullifying immune escape, by blocking the binding of PD‐1 on the surface of T cells to PD‐L1 on the surface of tumor cells.14 Here, CD274 is linked to neoplasm.